Roadmap to First-in-Class: A Novel Target for Neuropathic Pain

Millions suffer from debilitating neuropathic pain, which is poorly controlled with available analgesics. Indeed, more than 90% of subjects in one study continued to report moderate to severe pain even while they were taking prescribed medications1, indicating a significant unmet medical need in this area.

Ion channel targets hold promise as a therapeutic approach to neuropathic pain, and in this webinar, Professor Peter McNaughton of King’s College London joins Charles River scientists to describe his innovative work discovering a potential new drug for one such target. Learn from the project team’s experiences as they detail how the project progressed from the initial grant application, through milestones in assay development, screening, medicinal chemistry, in vivo model development and compound evaluation, and into its current state.

Presenters

  • Professor Peter McNaughton, FMedSci, Professor of Pharmacology, King’s College London
  • Sue Cramp, PhD, Team Leader, Chemistry, Charles River
  • Gary Clark, PhD, Research Fellow, Integrated Biology, Charles River


1Schaefer, et al. Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study. ClinicoEconomics and Outcomes Research. 2014; 6: 483-496.